DOCSLIB.ORG

Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis Review Article Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis Debajit Dey and Manidipa Banerjee* Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India Abstract When such inflammation, as manifested in symptoms such as jaundice, nausea, abdominal pain, malaise etc, is caused Viral hepatitis remains a significant worldwide threat, in spite by viral infections, the condition is referred to as viral hepatitis.1 of the availability of several successful therapeutic and vacci- Five hepatotropic viruses – named hepatitis A, B, C, D and nation strategies. Complications associated with acute and E viruses – target liver cells in humans and cause acute and chronic infections, such as liver failure, cirrhosis and hepato- chronic hepatitis. In addition, other viruses such as the cellular carcinoma, are the cause of considerable morbidity adenovirus, cytomegalovirus (CMV) and Epstein-Barr virus and mortality. Given the significant burden on the healthcare (EBV), occasionally cause symptoms of hepatitis.2 system caused by viral hepatitis, it is essential that novel, While an acute infection in healthy, immunocompetent more effective therapeutics be developed. The present review individuals is cleared spontaneously, complications like cir- attempts to summarize the current treatments against viral rhosis, hepatocellular carcinoma (HCC) and fulminant hepatic hepatitis, and provides an outline for upcoming, promising failure (FHF) may arise in immunocompromised individuals, new therapeutics. Development of novel therapeutics requires due to associated secondary reasons such as existing infec- an understanding of the viral life cycles and viral effectors in tions, alcohol abuse, or genetic predisposition.1,3 HCC, the molecular detail. As such, this review also discusses virally- third leading cause of cancer-related deaths worldwide,4 is encoded effectors, found to be essential for virus survival closely associated with hepatitis B virus (HBV) infections. and replication in the host milieu, which may be utilized as Even though the therapeutic strategies devised till date are potential candidates for development of alternative therapies targeted towards chronic infections, treatment options in the future. become severely limited for advanced stage patients.1 In addi- © 2016 The Second Affiliated Hospital of Chongqing Medical tion, current medications have significant side-effects, which University. Published by XIA & HE Publishing Inc. All rights poses an issue with disease management. Hence, there is an reserved. urgent requirement for safer and more potent drugs. This review will focus on the therapeutics currently avail- able for treating viral hepatitis of all forms. In addition, the potential of new therapeutics and targeted inhibitor-based Introduction therapies against viral membrane-penetrating peptides and viroporins, a group of virally encoded proteins involved in Hepatitis is a medical condition wherein the liver undergoes facilitating replication and other specific steps in the viral life inflammation due to a plethora of reasons, including drug cycle, are also discussed. abuse, excessive alcohol abuse, disease conditions etc.1 Life cycle of hepatotropic viruses Keywords: Viral hepatitis; Viroporin; Inhibitor. Abbreviations: CMV, Cytomegalovirus; EBV, Epstein-Barr virus; HCC, Hepatocel- Life cycles of the known hepatotropic viruses – particularly A, lular carcinoma; FHF, Fulminant hepatic failure; HBV, Hepatitis B virus; HAV, B, C and E – have been studied in significant detail. Although Hepatitis A virus; HCV, Hepatitis C virus; HEV, Hepatitis E virus; HDV, Hepatitis D virus; HAVcr-1/TIM-1, Hepatitis A virus cellular receptor 1/T-cell immunoglobulin the lack of appropriate cell culture systems, and the slow- and mucin domain 1; IRES, Internal ribosome entry site; 5’-UTR, 5’-Untranslated growing nature of the virus, has hampered studies, consid- region; L-SIGN, Liver/lymph node-specific intercellular adhesion molecule-3- erable information is available on the entry, replication and grabbing integrin; DC-SIGN, Dendritic cell-specific intercellular adhesion mole- exit mechanisms of these viruses, and on specific host- cule-3; GAG, glycosaminoglycan; HSC70, Heat shock cognate 70 protein; HSPG, Heparan sulfate proteoglycans; Grp78, Glucose-regulated protein 78; HSP90, Heat interacting partners for each virus. Hepatitis A virus (HAV) is shock protein 90; ORF1, Open reading frame 1; NTCP, sodium taurocholate cotrans- thought to associate with a cell-surface protein receptor, porting polypeptide; cccDNA, covalently closed circular DNA; PK, Protein kinase; HAVcr-1/TIM-1 (Hepatitis A virus cellular receptor 1/T-cell NA, Nucleos(t)ide analog; IFN, Interferon; L-HBsAg, Large hepatitis B surface immunoglobulin and mucin domain 1), a member of the antigen; HDAg, Hepatitis D antigen; PegIFN-a, Pegylated IFN-a,SVR,Sustained virological response; HBeAg, Hepatitis B e antigen; HBIg, Hepatitis B immunoglo- immunoglobulin superfamily, by which it gains entry into 5 bulin; CHB, Chronic hepatitis B; DAAs, Direct-acting antivirals; ZFNs, Zinc finger host cells. Post-entry, translation of the positive-sense RNA nucleases; TALEN’s, Transcription activator-like effector nucleases; CRISPR, Clus- genome by the host ribosomal machinery, mediated via the tered regulatory interspaced short palindromic repeats; RNAi, RNA interference; presence of an internal ribosome entry site (IRES) encoded HMA, Hexamethylene amilorides; NN-DNJ, N-nonyl deoxynojirimycin. ’ Received: 08 June 2016; Revised: 14 September 2016; Accepted: 14 September in the 5 -untranslated region (UTR) of viral RNA, results in 2016 the production of a large viral polyprotein. The polyprotein is q DOI: 10.14218/JCTH.2016.00025. cleaved into structural (VP1-2A, VP2, VP3, VP4) and non- *Correspondence to: Dr. Manidipa Banerjee, Kusuma School of Biological Scien- structural proteins (2B, 2C, 3A, 3B, 3C, 3D) as well as inter- ces, Indian Institute of Technology Delhi, Block 1A, Hauz Khas, New Delhi pro 110016, India. Tel: +91-11-26597538, Fax: +91-11-26597530, E-mail: mbanerjee@ mediates (3CD, 2BC etc) by a virally-encoded protease 3C . bioschool.iitd.ac.in Following the cleavage event, the viral RNA replicase 248 Journal of Clinical and Translational Hepatology 2016 vol. 4 | 248–257 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Dey D. et al: Inhibitors for viral hepatitis synthesizes a minus-sense strand corresponding to the viral transcriptase and the nucleocapsid (pregenomic). In addition, RNA genome, which serves as a template for the production transcripts encoding the surface antigens (subgenomic) are of multiple plus-sense strands. Meanwhile, structural proteins also produced. Both pre- and subgenomic transcrpits are assemble to form virions, which package a majority of the transferred to the cytosol. Surface protein synthesis, to gen- plus-sense RNA generated during replication. Two specific erate core and subviral particles, occurs in the ER. Translation cleavage events result in generation of mature infectious products (viral polymerase and core protein) of the prege- virions - the VP1-2A precursor cleavage and the VP4/VP2 nomic RNA associate with protein kinases (PKs),26,27 junctional cleavage.6–11 Virions are subsequently released HSPs27,28 and pregenomic RNA to yield mature core particles, from the apical membrane of infected hepatocytes.11 which are either released from infected cells, or are recircu- Entry of hepatitis C virus (HCV) into target host cells is a lated to the nucleus to maintain the cccDNA level.25,28 Inter- multistep event, requiring several host components. The estingly, while subviral particles are released via the secretory cellular receptors and surface molecules, which are thought pathway involving the Golgi and ER, mature core particles are to be involved in this process, include the C-type lectins liver/ released through multivesicular particles.25 lymph node-specific ICAM-3-grabbing integrin (L-SIGN) and Although not much is known regarding the cellular entry dendritic cell (DC)-specific intercellular adhesion molecule-3 process of hepatitis D virus (HDV), studies have suggested (ICAM-3)-grabbing nonintegrin (DC-SIGN), glycosaminogly- similarities with the HBV entry pathway involving interaction cans (GAGs), claudins 6 and 9 and CD-81.12–14 Binding to of HSPGs and NTCPs with the viral large hepatitis B surface cellular receptor(s) is primarily mediated by the viral envelope antigen (L-HBsAg; pre-S1 domain).24,29 Post-entry, transfer proteins E1 and E2. Post-entry, the virus nucleocapsid disas- of the RNA genome to the nucleus is facilitated by the virally- sembles releasing the plus-sense RNA genome in the cell encoded hepatitis D antigen (HDAg).30 Within the nucleus, cytosol, which acts as a template for 5’-IRES mediated trans- host RNA polymerases initiate genome replication, which lation. The single HCV polyprotein generated during transla- proceeds via a rolling circle mechanism.30 Subsequent tran- tion, like the corresponding HAV polypeptide, also undergoes scriptional and translational events lead to the production of protease mediated co- and post-processing to yield the entire the large delta antigen which undergoes prenylation prior to repertoire of viral structural and non-structural
Load more

Recommended publications
  • Immunogenicity and Efficacy Testing in Chimpanzees of an Oral Hepatitis B Vaccine Based on Live Recombinant Adenovirus
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 6763-6767, September 1989 Medical Sciences Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus (adenovirus animal model/adenovirus-vectored vacdnes) MICHAEL D. LUBECK*, ALAN R. DAVIS*, MURTY CHENGALVALA*, ROBERT J. NATUK*, JOHN E. MORIN*, KATHERINE MOLNAR-KIMBER*, BRUCE B. MASON*, BHEEM M. BHAT*, SATOSHI MIZUTANI*, PAUL P. HUNG*, AND ROBERT H. PURCELLO *Wyeth-Ayerst Research, Biotechnology and Microbiology Division, P.O. Pox 8299, Philadelphia, PA 19101; and tLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 Contributed by Robert H. Purcell, May 30, 1989 ABSTRACT As a major cause of acute and chronic liver which, because oftheir wide prior usage, are good candidates disease as well as hepatocellular carcinoma, hepatitis B virus as vectors. Other less well-characterized small animal models (HBV) continues to pose significant health problems world- for human adenoviruses have been occasionally reported wide. Recombinant hepatitis B vaccines based on adenovirus (11-13) but are likewise nonpermissive for Ad4 and Ad7 vectors have been developed to address global needs for infections (unpublished data). An early study of animal effective control of hepatitits B infection. Although consider- species including nonhuman primates indicated that human able progress has been made in the construction ofrecombinant adenoviruses do not induce acute respiratory disease in adenoviruses that express large amounts of HBV gene prod- monkeys or chimpanzees following intranasal inoculations ucts, preclinical immunogenicity and efficacy testing of candi- (14). Serological data, however, indicated that such experi- date vaccines has remained difficult due to the lack ofa suitable mental infections occasionally induced anti-adenovirus anti- animal model.
    [Show full text]
  • Hepatitis B Fast Facts Everything You Need to Know in 2 Minutes Or Less!
    Hepatitis B Foundation Cause for a Cure www.hepb.org Hepatitis B Fast Facts Everything you need to know in 2 minutes or less! Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV) that attacks liver cells and can lead to liver failure, cirrhosis (scarring) or cancer of the liver. The virus is transmitted through contact with blood and bodily fluids that contain blood. Most people are able to fight off the hepatitis B infection and clear the virus from their blood. This may take up to six months. While the virus is present in their blood, infected people can pass the virus on to others. Approximately 5-10% of adults, 30-50% of children, and 90% of babies will not get rid of the virus and will develop chronic infection. Chronically infected people can pass the virus on to others and are at increased risk for liver problems later in life. The hepatitis B virus is 100 times more infectious than the AIDS virus. Yet, hepatitis B can be pre- vented with a safe and effective vaccine. For the 400 million people worldwide who are chronically infected with hepatitis B, the vaccine is of no use. However, there are promising new treatments for those who live with chronic hepatitis B. In the World: • This year alone, 10 to 30 million people will become infected with the hepatitis B virus (HBV). • The World Health Organization estimates that 400 million people worldwide are already chronically infected with hepatitis B.
    [Show full text]
  • Prevention & Control of Viral Hepatitis Infection
    Prevention & Control of Viral Hepatitis Infection: A Strategy for Global Action © World Health Organization 2011. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Table of contents Disease burden 02 What is viral hepatitis? 05 Prevention & control: a tailored approach 06 Global Achievements 08 Remaining challenges 10 World Health Assembly: a mandate for comprehensive prevention & control 13 WHO goals and strategy
    [Show full text]
  • Inhibition of HIV-1 by an Anti-Integrase Single-Chain Variable
    Gene Therapy (1999) 6, 660–666 1999 Stockton Press All rights reserved 0969-7128/99 $12.00 http://www.stockton-press.co.uk/gt Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection M BouHamdan1, L-X Duan1, RJ Pomerantz1 and DS Strayer1,2 1The Dorrance H Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine; and 2Department of Pathology, Anatomy and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA Human immunodeficiency virus type I (HIV-1) encodes the SFv-IN was confirmed by Western blotting and several proteins that are packaged into virus particles. Inte- immunofluorescence staining, which showed that Ͼ90% of grase (IN) is an essential retroviral enzyme, which has SupT1 T-lymphocytic cells treated with SV(Aw) expressed been a target for developing agents to inhibit virus repli- the SFv-IN protein without selection. When challenged, cation. In previous studies, we showed that intracellular HIV-1 replication, as measured by HIV-1 p24 antigen expression of single-chain variable antibody fragments expression and syncytium formation, was potently inhibited (SFvs) that bind IN, delivered via retroviral expression vec- in cells expressing SV40-delivered SFv-IN. Levels of inhi- tors, provided resistance to productive HIV-1 infection in bition of HIV-1 infection achieved using this approach were T-lymphocytic cells. In the current studies, we evaluated comparable to those achieved using murine leukemia virus simian-virus 40 (SV40) as a delivery vehicle for anti-IN (MLV) as a transduction vector, the major difference being therapy of HIV-1 infection.
    [Show full text]
  • Evolution of Hepatitis B Serological Markers in HIV Coinfected Patients: a Case Study
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Cadernos Espinosanos (E-Journal) Rev Saúde Pública 2017;51:24 Artigo Original http://www.rsp.fsp.usp.br/ Evolution of hepatitis B serological markers in HIV coinfected patients: a case study Ana Luiza de Castro Conde ToscanoI,II, Maria Cássia Mendes CorrêaII,III I Instituto de Infectologia Emílio Ribas. São Paulo, SP, Brasil II Departamento de Doenças Infecciosas. Faculdade de Medicina. Universidade de São Paulo. São Paulo, SP, Brasil III Instituto de Medicina Tropical de São Paulo. Laboratório de Investigação Médica 52. São Paulo, SP, Brasil ABSTRACT OBJECTIVE: To describe the evolution of serological markers among HIV and hepatitis B coinfected patients, with emphasis on evaluating the reactivation or seroreversion of these markers. METHODS: The study population consisted of patients met in an AIDS Outpatient Clinic in São Paulo State, Brazil. We included in the analysis all HIV-infected and who underwent at least two positive hepatitis B surface antigen serological testing during clinical follow up, with tests taken six months apart. Patients were tested with commercial kits available for hepatitis B serological markers by microparticle enzyme immunoassay. Clinical variables were collected: age, sex, CD4+ T-cell count, HIV viral load, alanine aminotransferase level, exposure to antiretroviral drugs including lamivudine and/or tenofovir. RESULTS: Among 2,242 HIV positive patients, we identified 105 (4.7%) patients with chronic hepatitis B. Follow up time for these patients varied from six months to 20.5 years. All patients underwent antiretroviral therapy during follow-up. Among patients with chronic hepatitis B, 58% were hepatitis B “e” antigen positive at the first assessment.
    [Show full text]
  • Covalent Protein Display on Hepatitis B Core-Like Particles in Plants
    www.nature.com/scientificreports OPEN Covalent protein display on Hepatitis B core‑like particles in plants through the in vivo use of the SpyTag/SpyCatcher system Hadrien Peyret1*, Daniel Ponndorf1, Yulia Meshcheriakova1, Jake Richardson2 & George P. Lomonossof1 Virus‑like particles (VLPs) can be used as nano‑carriers and antigen‑display systems in vaccine development and therapeutic applications. Conjugation of peptides or whole proteins to VLPs can be achieved using diferent methods such as the SpyTag/SpyCatcher system. Here we investigate the conjugation of tandem Hepatitis B core (tHBcAg) VLPs and the model antigen GFP in vivo in Nicotiana benthamiana. We show that tHBcAg VLPs could be successfully conjugated with GFP in the cytosol and ER without altering VLP formation or GFP fuorescence. Conjugation in the cytosol was more efcient when SpyCatcher was displayed on tHBcAg VLPs instead of being fused to GFP. This efect was even more obvious in the ER, showing that it is optimal to display SpyCatcher on the tHBcAg VLPs and SpyTag on the binding partner. To test transferability of the GFP results to other antigens, we successfully conjugated tHBcAg VLPs to the HIV capsid protein P24 in the cytosol. This work presents an efcient strategy which can lead to time and cost saving post‑translational, covalent conjugation of recombinant proteins in plants. Virus-like particles (VLPs) are protein complexes that are similar or even indistinguishable from native viral particles in terms of their structure and antigenicity. Tey do not contain the viral genome and hence, they cannot replicate and are not pathogenic. Te repetitive surface structure and a typical size range of 20–200 nm make VLPs highly immunogenic and they can induce a strong humoral and cellular immune response1.
    [Show full text]
  • A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B Pres2 Surface Antigen
    biosensors Article A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B preS2 Surface Antigen Yangyang Cai 1,2,3, Jun Yan 1,2,3, Li Zhu 4, Hengliang Wang 4 and Ying Lu 1,2,3,* 1 College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China; [email protected] (Y.C.); [email protected] (J.Y.) 2 Laboratory of Quality & Safety Risk Assessment for Aquatic Products on Storage and Preservation (Shanghai), Ministry of Agriculture, Shanghai 201306, China 3 Shanghai Engineering Research Center of Aquatic-Product Processing and Preservation, Shanghai 201306, China 4 Beijing Institute of Biotechnology, Beijing 100071, China; [email protected] (L.Z.); [email protected] (H.W.) * Correspondence: [email protected]; Tel.: +86-021-6190-0503 Received: 24 September 2020; Accepted: 27 October 2020; Published: 31 October 2020 Abstract: Hepatitis B is a globally prevalent viral infectious disease caused by the hepatitis B virus (HBV). In this study, an immunochromatographic assay (ICA) for the rapid detection of hepatitis B preS2 antigen (preS2Ag) was established. The magnetic nanoparticles (MNPs) indirectly labelled with goat anti-mouse (GAM) secondary antibody were applied as a nanoprobe for free preS2 antibody (preS2Ab) capturing and signal amplification. By employing sample pre-incubation processing as well, preS2Ag-preS2Ab was sufficiently caught by the GAM-MNPs probe in 5 min. A qualitative sensitivity of 625 ng/mL was obtained by naked-eye observation within 15–20 min. A standard curve (0–5000 ng/mL) was established, with a quantitative limit of detection (LOD) of 3.6 ng/mL, based on the stability and penetrability of the magnetic signal characteristics.
    [Show full text]
  • Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
    Hindawi Publishing Corporation Scienti�ca Volume 2012, Article ID 478631, 22 pages http://dx.doi.org/10.6064/2012/478631 Review Article Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis Peter Karayiannis Section of Hepatology and Gastroenterology, Department of Medicine, Imperial College, St Mary’s Campus, London W2 1PG, UK Correspondence should be addressed to Peter Karayiannis; [email protected] Received 17 September 2012; Accepted 8 October 2012 Academic Editors: M. Clementi and W. Vogel Copyright © 2012 Peter Karayiannis. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. e development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus (HBV, HCV, and HDV). e introduction of direct acting antivirals (DDAs) for the treatment of HBV carriers has permitted the long- term use of these compounds for the continuous suppression of viral replication, whilst in the case of HCV in combination with the standard of care [SOC, pegylated interferon (PegIFN), and ribavirin] sustained virological responses (SVRs) have been achieved with increasing frequency. Progress in the case of HDV has been slow and lacking in signi�cant breakthroughs.is paper aims to summarise the current state of play in treatment approaches for chonic viral hepatitis patients and future perspectives. 1. Introduction recombinant subsequently, both of which have more recently been superceded by the pegylated form (PegIFN), which Conservative estimates of the number of individuals world- requires intramuscular injection only once a week as opposed wide who are thought to be chronically infected with either to three times a week with the previous forms.
    [Show full text]
  • Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for Biomedical Research, Inc
    VIROLOGICA SINICA, August 2010, 25 (4):246-266 DOI 10.1007/s12250-010-3140-2 © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2010 Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for BioMedical Research, Inc. Cambridge, Massachusetts 02139, USA) Abstract: Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
    [Show full text]
  • Hepatitis B? HEPATITIS B Hepatitis B Is a Contagious Liver Disease That Results from Infection with the Hepatitis B Virus
    What is Hepatitis B? HEPATITIS B Hepatitis B is a contagious liver disease that results from infection with the Hepatitis B virus. When first infected, a person can develop Are you at risk? an “acute” infection, which can range in severity from a very mild illness with few or no symptoms to a serious condition requiring hospitalization. Acute Hepatitis B refers to the first 6 months after someone is exposed to the Hepatitis B virus. Some people are able to fight the infection and clear the virus. For others, the infection remains and leads to a “chronic,” or lifelong, illness. Chronic Hepatitis B refers to the illness that occurs when the Hepatitis B virus remains in a person’s body. Over time, the infection can cause serious health problems. How is Hepatitis B spread? Hepatitis B is usually spread when blood, semen, or other body fluids from a person infected with the Hepatitis B virus enter the body of someone who is not infected. This can happen through having sex with an infected partner; sharing needles, syringes, or other injection drug equipment; or from direct contact with the blood or open sores of an infected person. Hepatitis B can also be passed from an infected mother to her baby at birth. Who should be tested for Hepatitis B? Approximately 1.2 million people in the United States and 350 million people worldwide have Hepatitis B. Testing for Hepatitis B is recommended for certain groups of people, including: Most are unaware of their infection. ■ People born in Asia, Africa, and other regions with moderate or high rates Is Hepatitis B common? of Hepatitis B (see map) Yes.
    [Show full text]
  • Reviews in Basic and Clinical Gastroenterology
    GASTROENTEROLOGY 2010;138:447–462 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY REVIEWS IN BASIC AND CLINICAL John P. Lynch and David C. Metz, Section Editors GASTROENTEROLOGY Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection CHRISTOPH SARRAZIN and STEFAN ZEUZEM J. W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany Chronic hepatitis C virus (HCV) infection is one of agents that are also named specific, targeted antiviral the major causes of cirrhosis, hepatocellular carci- therapies (STAT-C) for HCV infection are in phase 1–3 noma, and liver failure that leads to transplantation. trials. We review resistance to DAA agents, focusing on The current standard treatment, a combination of compounds in development such as reagents that target pegylated interferon alfa and ribavirin, eradicates the the HCV nonstructural (NS)3 protease, the NS5A pro- virus in only about 50% of patients. Directly acting tein, and the RNA-dependent RNA polymerase NS5B. We antiviral (DAA) agents, which inhibit HCV replica- also discuss indirect inhibitors or compounds that in- tion, are in phase 1, 2, and 3 trials; these include hibit HCV replication by not yet completely resolved reagents that target the nonstructural (NS)3 protease, mechanisms, such as cyclophilin inhibitors, nitazox- the NS5A protein, the RNA-dependent RNA-polymer- anide, and silibinin (Table 1, Figure 1). ase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell Parameters That Affect Resistance proteins. Because of the high genetic heterogeneity of Heterogeneity of HCV HCV and its rapid replication, monotherapy with HCV has a high rate of turnover; its half-life was DAA agents poses a high risk for selection of resistant estimated to be only 2–5 hours, with the production and variants.
    [Show full text]
  • WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T (51) International Patent Classification: (74) Agent: PINO, Mark, J.; Connolly Bove Lodge & Hutz C07D 417/04 (2006.01) A61K 31/542 (2006.01) LLP, 1875 Eye Street, Nw, Suite 1100, Washington, DC C07D 513/04 (2006.01) A61P 31/14 (2006.01) 20006 (US). A61K 31/5415 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 12/032297 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 5 April 2012 (05.04.2012) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/472,286 6 April 201 1 (06.04.201 1) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US) : ANADYS (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC.
    [Show full text]